- Trials with a EudraCT protocol (125)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
125 result(s) found for: Genotype frequency.
Displaying page 1 of 7.
EudraCT Number: 2010-018295-24 | Sponsor Protocol Number: AI444-010 | Start Date*: 2010-07-12 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection Revised Protocol Number ... | |||||||||||||
Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) FR (Completed) IT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000836-27 | Sponsor Protocol Number: AI444-026 | Start Date*: 2011-09-30 | |||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
Full Title: An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C Revised Protocol Number 05; Incorporates Ame... | |||||||||||||
Medical condition: HEPATITIS C VIRUS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) GB (Completed) ES (Completed) SE (Completed) DK (Completed) IT (Completed) AT (Completed) NL (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000151-10 | Sponsor Protocol Number: TAR-PRO | Start Date*: 2017-08-02 |
Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario La Paz | ||
Full Title: Antiretroviral therapy proviral genotype-guided: pilot-proof of concept clinical trial. | ||
Medical condition: Human Immunodeficiency Virus | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022408-28 | Sponsor Protocol Number: AI444-031 | Start Date*: 2010-12-10 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 2B Pilot Study of Short-Term Treatment of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 2 or 3 Infection. | |||||||||||||
Medical condition: Chronic hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002808-25 | Sponsor Protocol Number: AI444-281 | Start Date*: 2015-04-16 |
Sponsor Name:Academic Medical Center Amsterdam | ||
Full Title: Immune phenotyping in chronic hepatitis C patients treated with Sofosbuvir and Daclatasvir combination with or without Ribavirin for 12 or 24 weeks -SODA study | ||
Medical condition: Chronic hepatitis C | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000070-28 | Sponsor Protocol Number: AI444-062 | Start Date*: 2012-08-13 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 2, Open-Label Study of Daclatasvir (BMS-790052) and TMC435 in Combination With or Without Ribavirin (RBV) For Treatment-Naive Subjects or Null Responders to Prior Peginterferon Alfa (PegIFN... | |||||||||||||
Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004114-99 | Sponsor Protocol Number: FERTIRES-2016 | Start Date*: 2017-05-18 |
Sponsor Name:AB-BIOTICS | ||
Full Title: USE OF P.N680S POLYMORPHISM TO CHOOSE THE EXOGEN FSH DOSE IN CONTROLLED OVARIAN HYPERSTIMULATION: A PROSPECTIVE TRIAL | ||
Medical condition: Infertility | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002458-66 | Sponsor Protocol Number: AI443-113 | Start Date*: 2013-12-13 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Subjects with Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis | |||||||||||||
Medical condition: HEPATITIS C VIRUS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005310-28 | Sponsor Protocol Number: AI444-326 | Start Date*: 2015-02-13 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Open-Label, Randomized Study of Daclatasvir, Sofosbuvir, and Ribavirin for 12 vs. 16 weeks in Treatment-Naïve and Treatment-Experienced Patients with Genotype 3 Chronic Hepatitis C Infection with C... | |||||||||||||
Medical condition: Genotype 3 Chronic Hepatitis C infection with Compensated Advanced Fibrosis/Cirrhosis (F3/F4) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004393-10 | Sponsor Protocol Number: GN18CA068 | Start Date*: 2019-07-17 | |||||||||||
Sponsor Name:NHS Greater Glasgow & Clyde [...] | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, cross-over trial of zibotentan in microvascular angina | |||||||||||||
Medical condition: Microvascular Angina and impaired exercise intolerance. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013652-69 | Sponsor Protocol Number: AI447-016 | Start Date*: 2010-01-19 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 2a/2b study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects with Genotypes 1 and 4 Chronic Hepatitis C Infection. | |||||||||||||
Medical condition: Chronic Hepatitis C Virus Infection (Genotypes 1 and 4) in Treatment-Naive Subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Completed) DE (Completed) ES (Completed) IE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000523-40 | Sponsor Protocol Number: HAI115879 | Start Date*: 2012-09-11 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Devlopment Ltd | |||||||||||||
Full Title: A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of G... | |||||||||||||
Medical condition: Hepatitis C virus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002793-23 | Sponsor Protocol Number: AI444-042 | Start Date*: 2012-03-07 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3 Evaluation of Daclatasvir (BMS-790052) in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotype 4 Revised Protocol Number ... | |||||||||||||
Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021785-30 | Sponsor Protocol Number: A4001095 | Start Date*: 2011-12-07 | |||||||||||
Sponsor Name:ViiV Healthcare UK Limited | |||||||||||||
Full Title: A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFE... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) SE (Prematurely Ended) FI (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) AT (Completed) DK (Prematurely Ended) NL (Completed) PT (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001956-31 | Sponsor Protocol Number: 2015-001956-31 | Start Date*: 2015-06-09 | |||||||||||
Sponsor Name:Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre. | |||||||||||||
Full Title: Direct acting antiviral therapy of hepatitis C in Denmark: treatment response, adverse events and resistance associated variants | |||||||||||||
Medical condition: Patients with chronic hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005422-21 | Sponsor Protocol Number: AI447-029 | Start Date*: 2012-06-13 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3, Open-Label Study with Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who Are Null or Partial Responders to Peginterfer... | |||||||||||||
Medical condition: Chronic Hepatitis C Virus Infection (Genotypes 1 and 4) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) NL (Completed) ES (Completed) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019767-11 | Sponsor Protocol Number: Ö-PKU1 | Start Date*: 2010-09-08 |
Sponsor Name:Graz Medical University | ||
Full Title: Ö-PKU 1 – Evaluation of a Test for the identication of BH4 responsive PKU patients | ||
Medical condition: Hyperphenylalaninaemia (HPA) in adult and paediatric patients of 4 years of age and over with phenylketonuria (PKU). | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001647-12 | Sponsor Protocol Number: ARB-001467-003 | Start Date*: 2018-02-06 | |||||||||||
Sponsor Name:Arbutus Biopharma Corporation | |||||||||||||
Full Title: A Phase 2a, Open-Label, Study Evaluating the Safety and Anti-Viral Activity of ARB-001467 in Non-Cirrhotic, HBeAg-Negative Subjects with Chronic HBV Infection (Genotype A or B) in Combination with ... | |||||||||||||
Medical condition: Hepatitis B virus e-antigen (HBeAg)-negative subjects with chronic hepatitis B virus infection (CHB) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000599-87 | Sponsor Protocol Number: 011094 | Start Date*: 2016-06-01 | |||||||||||
Sponsor Name:Queen Mary University of London | |||||||||||||
Full Title: Response guided therapy with daclatasvir, sofosbuvir and ribavirin for 12 or 24 weeks in patients with genotype 3 chronic hepatitis C virus: is longer therapy worthwhile? | |||||||||||||
Medical condition: Adult patients chronically infected with genotype 3 hepatitis C virus with cirrhosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000706-36 | Sponsor Protocol Number: P05498 | Start Date*: 2008-09-30 | |||||||||||
Sponsor Name:Hannover Medical School; Competence Network Viral Hepatitis (Hep-Net) | |||||||||||||
Full Title: Optimization of treatment for patients with chronic hepatitis C infected with HCV-genotype 2 or 3: 12 vs. 24 weeks of treatment extension for patients without rapid virological response | |||||||||||||
Medical condition: chronic hepatitis c infection genotype 2/3 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
